Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Recombinant tissue-type plasminogen activator (rtPA) is the only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients in the United States received rtPA. Given incentives from regulatory agencies and payors to increase rtPA use, we hypothesized that rtPA use in the United States would increase from 2005 to 2009.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Stroke

Title: Stroke

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1524-4628

ISSN (Print): 0039-2499

Publication date (Electronic): Jul 2011

Volume: 42

Issue: 7

Affiliations

[1 ] UC Neuroscience Institute, Department of Emergency Medicine, 231 Albert Sabin Way, ML 0769, University of Cincinnati Medical Center, Cincinnati, OH 45267-0525, USA. opeolu.adeoye@uc.edu

Article

Mid ID: NIHMS308994 Publisher Item ID: STROKEAHA.110.612358

DOI: 10.1161/STROKEAHA.110.612358

PMC ID: 4114342

PubMed ID: 21636813

SO-VID: d1efc784-4eb8-4045-a763-9f1d49b46f0e

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.